Veracyte Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Veracyte stock.
View analyst ratings for Veracyte or view top-rated stocks.

Wall Street analysts have given Veracyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Veracyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Veracyte is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Veracyte.

Veracyte, Inc. (NASDAQ:VCYT) issued its quarterly earnings results on Monday, May, 10th. The biotechnology company reported ($0.11) EPS for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.01. Veracyte had a negative trailing twelve-month return on equity of 12.27% and a negative net margin of 30.46%.
View Veracyte's earnings history.

Veracyte's stock was trading at $23.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VCYT shares have increased by 69.4% and is now trading at $39.89.
View which stocks have been most impacted by COVID-19.

Veracyte issued an update on its FY 2021 earnings guidance on Tuesday, May, 11th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $190 million-$200 million, compared to the consensus revenue estimate of $194.19 million.

8 Wall Street analysts have issued twelve-month target prices for Veracyte's shares. Their forecasts range from $48.00 to $65.00. On average, they expect Veracyte's share price to reach $58.43 in the next twelve months. This suggests a possible upside of 46.5% from the stock's current price.
View analysts' price targets for Veracyte or view top-rated stocks among Wall Street analysts.

Some companies that are related to Veracyte include Natera (NTRA), Invitae (NVTA), Elekta AB (publ) (EKTAY), CareDx (CDNA), Burning Rock Biotech (BNR), Fulgent Genetics (FLGT), Genetron (GTH), Castle Biosciences (CSTL), RadNet (RDNT), Renalytix AI (RNLX), DermTech (DMTK), Personalis (PSNL), Celcuity (CELC), Exagen (XGN) and Centogene (CNTG).
View all of VCYT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.14%), Artisan Partners Limited Partnership (6.98%), Nikko Asset Management Americas Inc. (4.89%), Sumitomo Mitsui Trust Holdings Inc. (4.85%), New York State Common Retirement Fund (1.51%) and Oak Ridge Investments LLC (1.46%). Company insiders that own Veracyte stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Mark Ho and Robert S Epstein.
View institutional ownership trends for Veracyte.

VCYT stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, BNP Paribas Arbitrage SA, State of New Jersey Common Pension Fund D, Sumitomo Mitsui Trust Holdings Inc., Fiera Capital Corp, Russell Investments Group Ltd., Aigen Investment Management LP, and Victory Capital Management Inc.. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Mark Ho, and Robert S Epstein.
View insider buying and selling activity for Veracyte or view top insider-selling stocks.

VCYT stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, BlackRock Inc., Oak Ridge Investments LLC, Jennison Associates LLC, New York State Common Retirement Fund, Fisher Asset Management LLC, Rafferty Asset Management LLC, and Swiss National Bank.
View insider buying and selling activity for Veracyte or or view top insider-buying stocks.

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VCYT stock can currently be purchased for approximately $39.89.

Veracyte has a market capitalization of $2.68 billion and generates $120.37 million in revenue each year. The biotechnology company earns $-12,600,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

Veracyte employs 320 workers across the globe.

The official website for Veracyte is www.veracyte.com.

Veracyte is headquartered at 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]